RSV Diagnostics Market Overview:
Over the projected period, the RSV diagnostics market is predicted to grow in importance. During the projected period of 2020–2030, it is predicted that the worldwide RSV diagnostics market will grow at a CAGR of 10.7%. RSV (Respiratory Syncytial Virus) is a virus that causes illness in the lower respiratory tract. RSV is a leading cause of serious respiratory infection in preterm newborns and children under five years old. It can cause symptoms ranging from a slight cold to bronchiolitis and pneumonia.
The primary drivers driving the market's growth include the rising incidence of respiratory infections, the growing newborn population base, the rising need for in-vitro diagnostics, and the rising demand for point-of-care facilities. According to the World Health Organization (WHO), pneumonia caused 16 percent of all fatalities in children under the age of five in 2015, with 9, 20,136 children dying.
A mild Respiratory Syncytial Virus (RSV) affects young children's upper respiratory systems. Coughing, sore throats, wheezing, and runny noses frequently characterize RSV. Rapid protein detection relies heavily on antigen-antibody reactions. Antibodies can be exceedingly specific, binding to only a small portion of an antigen, and can distinguish between very similar antigens. They detect proteins based on both their structure and content. Due to their weakened immune systems, older persons are more susceptible than young adults to significant consequences from RSV. The primary diagnostic procedure is a physical examination by the physician. In extreme cases, the doctor does tests, including molecular diagnostics for virus identification, serology tests, and quick antigen detection tests.
Initial signs of respiratory syncytial viruses (RVs) include a moderate cold with symptoms such as congestion, a runny nose, coughing, sore throat, and fever. Young newborns may exhibit signs of exhaustion, irritability, and respiratory issues. Under typical circumstances, these symptoms subside after a few days. The rising incidence of respiratory syncytial virus infections worldwide, increased investments, technical developments, product approvals and introductions, government efforts, and other important strategies the leading market players take are the factors driving the studied industry's growth. Advanced methods like bio- and nanotechnology (PCR) are helping to develop current RSV detection technologies, such as western blot, enzyme-linked immunosorbent test (ELISA), direct immunofluorescence, and real-time polymerase chain reaction. In addition, the governments of several nations subsidize research and development projects to develop new therapeutics.
The appetite for the RSV diagnostics market is driven by factors such as the increased frequency of chronic diseases, such as respiratory disorders, in the neonatal population, the rising number of new newborns, and parental awareness raised by various health organizations. During the projected period, the respiratory syncytial virus (RSV) diagnostic market is anticipated to expand due to the rising need for point-of-care testing to diagnose RSV-infected individuals and developments in the field of markers such as proteomics and genomics. Furthermore, the market for respiratory syncytial virus (RSV) diagnostics is anticipated to grow due to the increased prevalence of RSV infections.
The global RSV diagnostics market is segmented on the basis of the product, method, and end-user.
On the basis of product, the market is classified into kits and assays, instruments, and other products.
The global RSV diagnostics market on the basis of the method is segmented into molecular diagnostics, rapid antigen detection test, gel microdroplets, flow cytometry, and others. The rapid antigen detection tests are further classified into enzyme-linked immunosorbent assays, immunofluorescence assays, and other rapid antigen detection tests. The other rapid antigen detection tests are classified into chromatographic immunoassays and optical immunoassays.
News:The National Institutes of Health (NIH) has given Domus Diagnostics, a point-of-care diagnostics firm based in the United States, funding to improve their point-of-care nucleic acid detection and amplification test for simultaneous detection of COVID-19, Flu-A, Flu-B, and RSV. The award will assist in faster validation and expansion of Domus Diagnostics' testing platform for clinical study preparedness. It is worth up to $2.4M and is made possible by the NIH's Rapid Acceleration of Diagnostics (RADx®) Tech program. The Domus Diagnostics platform serves as an ultra-low-cost, zero-power testing framework that will generate revolutionary devices that make it possible to test for infectious diseases at home, in doctors' offices, or public testing facilities in a reliable, accurate, and efficient manner. The gadgets will make infectious illness testing substantially more accessible and affordable worldwide.
On basis of end-user, the market is segmented into hospitals and clinics, clinical laboratories, home care, and others.
Geographically, global RSV diagnostics market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The American RSV diagnostics market is further segmented into North America, and South America. North America is further classified as the US and Canada.
The Europe RSV diagnostics market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and Rest of Western Europe.
The Asia-Pacific RSV diagnostics market is segmented into Japan, China, India, Republic of Korea, Australia, and Rest of Asia-Pacific.
The Middle East & Africa RSV diagnostics market is segmented into the Middle East, and Africa.
Quest Diagnostics, Biomerieux, Becton, Dickinson, and Company (BD), Abbott, F. Hoffman-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Biocartis, Luminex, Hologic, Fast Track Diagnostics, Bio-Rad Laboratories Inc., Alere, Inc., Quidel Corporation, others are some prominent players in this market.
Regional Market Summary
Global RSV Diagnostics Market, by Region Market Share, 2017 (%)
Source: MRFR Analysis
The global RSV diagnostics market consists of four regions: the Americas, Europe, Asia-Pacific and the Middle East & Africa. The Americas is expected to dominate the RSV diagnostics market owing to the increasing incidences of RSV, rising healthcare expenditure, and technological developments in molecular diagnostics. For instance, according to the Centers for Disease Control and Prevention, annually in the United States, more than 57,000 children younger than five years old are hospitalized due to RSV infection.
Europe is anticipated to hold the second position in the global RSV diagnostics market. It is expected that the rising automation in vitro diagnostics, increasing occurrence of RSV diseases, and funding provided by the government are anticipated to drive the European market. For instance, according to the data stated by the University of Oxford, it is anticipated that over 30,000 babies and children below five years of age are hospitalized due to RSV in the UK every year.
The Asia-Pacific RSV diagnostics market consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region due to growing infectious disease burden including RSV infection, growing healthcare expenditure, and rising demand for RSV disease diagnosis. Moreover, China, India, and Japan are expected to be the fastest growing markets in the region due to the developing healthcare systems and growing numbers of government initiatives.
The Middle East and Africa is likely to hold the least share in the global RSV diagnostics market. However, growing awareness among the population and high investments by private market players, rising incidences of RSV in children in this region can boost the growth of the market.
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, Treatment assessment, competitive landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments & categories geographically presented are studied and are estimated based on primary & secondary research.
The extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the RSV diagnostics market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others.
Global RSV Diagnostics Market, by Product
- Kits and Assays
- Other Products
Global RSV Diagnostics Market, by Method
- Molecular Diagnostics
- Rapid Antigen Detection Tests
- Enzyme-Linked Immunosorbent Assays
- Immunofluorescence Assays
- Other rapid Antigen Detection Tests
- Chromatographic Immunoassays
- Optical Immunoassays
- Gel Microdroplets
- Flow Cytometry
Global RSV Diagnostics Market, by End-user
- Hospitals and Clinics
- Clinical Laboratory
Global RSV Diagnostics Market, by Region
- North America
- South America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- Republic of Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Quest Diagnostics
- Becton, Dickinson, and Company (BD)
- Hoffman-La Roche Ltd.
- Danaher Corporation
- Thermo Fisher Scientific
- Fast Track Diagnostics
- Bio-Rad Laboratories Inc.
- Alere, Inc.
- Quidel Corporation
Bio-Rad Laboratories Inc (Bio-Rad) is a company that develops, manufactures, and sells a variety of products and systems for use in life science research, healthcare, analytical chemistry, and other industries. Reagents, equipment, laboratory tools, test systems, informatics systems, test kits, and specialized quality controls are among the company's main products. Universities and medical schools, industrial research organizations, pharmaceutical manufacturers, government agencies, biotechnology researchers, food producers, food testing laboratories, reference laboratories, hospital and transfusion laboratories, and physician office laboratories are among the customers of Bio-products. Rad's
Danaher is a medical and industrial corporation whose products test, analyze, and diagnose. Its companies create, develop, and distribute goods and services for the professional, medical, dental, industrial, and commercial industries all over the world. Life Sciences, Diagnostics (research and clinical instruments), and Environmental & Applied Solutions (turbine pumps and air/water analysis and treatment devices) are Danaher's three segments. It has consumers in united states.Intended Audience
- Manufacturers and vendors of RSV diagnostics
- Research associations related to infectious diseases
- Various research and consulting firms
- Distributors of RSV diagnostics products
- Contract manufacturers of RSV diagnostics products
- Healthcare institutions
- Research institutes
Frequently Asked Questions (FAQ) :
The global RSV diagnostics market has the chance to score a CAGR of 10.7% during the forecast period covering 2020 to 2020.
Factors like lack of specific treatment options and a high number of other pathogens that can work in similar situations can impact the RSV diagnostics market growth.
The RSV diagnostics market has end users like hospitals & clinics, home care, clinical laboratories, and others.
The US would dominate the American RSV diagnostics market.
The global RSV diagnostics market would be controlled mostly by companies like Biomerieux, Quest Diagnostics, Abbott, F. Hoffman-La Roche Ltd., Becton, Dickinson, and Company (BD), Thermo Fisher Scientific, Danaher Corporation, Luminex, Hologic, Fast Track Diagnostics, Biocartis, Alere, Inc., Bio-Rad Laboratories Inc., Quidel Corporation, and others.
Key Questions Answered
Request Free Sample
- ✅Global Market Outlook
- ✅In-depth analysis of global and regional trends
- ✅Analyze and identify the major players in the market, their market share, key developments, etc.
- ✅To understand the capability of the major players based on products offered, financials, and strategies.
- ✅Identify disrupting products, companies, and trends.
- ✅To identify opportunities in the market.
- ✅Analyze the key challenges in the market.
- ✅Analyze the regional penetration of players, products, and services in the market.
- ✅Comparison of major players’ financial performance.
- ✅Evaluate strategies adopted by major players.
Why Choose Market Research Future?
Speak to Analyst
- ✅Vigorous research methodologies for specific market.
- ✅Knowledge partners across the globe
- ✅Large network of partner consultants.
- ✅Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- ✅Trusted by fortune 500 companies/startups/universities/organizations
- ✅Large database of 5000+ markets reports.
- ✅Effective and prompt pre- and post-sales support.